New cancer antibody GEN1079 enters first human testing
NCT ID NCT07387068
Summary
This is the first human trial testing an experimental antibody called GEN1079 in people with advanced solid tumors. The study aims to find safe doses and see early signs of whether the treatment helps control cancer. About 121 participants with specific advanced cancers will receive the antibody and be monitored closely for side effects and tumor response over approximately 33-67 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest, LLC
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START New York
RECRUITINGLake Success, New York, 11042, United States
Conditions
Explore the condition pages connected to this study.